Neflamapimod Improves Episodic Memory in Early Alzheimer’s Patients in Phase 2a Trial

Neflamapimod Improves Episodic Memory in Early Alzheimer’s Patients in Phase 2a Trial
Investigational therapy Neflamapimod led to significant improvements in episodic memory function in patients with early Alzheimer's disease, results from EIP Pharma's Phase 2a clinical trial show. "Significant unmet need exists for improved Alzheimer's treatments which is why we are so encouraged by these data demonstrating neflamapimod's potential to improve memory function in patients with Alzheimer's disease," John Alam, MD, EIP Pharma’s CEO, said in a press release"We look forward to reporting top-line results of the recently initiated REVERSE-SD Phase 2b clinical study in the second half of 2019."  Based on the findings, the company is now recruiting for the Phase 2b trial (NCT03402659) to confirm the positive effects of neflamapimod in patients with mild Alzheimer’s disease. The trial will enroll about 150 participants who will be randomized to receive either placebo or 40 mg pills of
Subscribe or to access all post and page content.

One comment

  1. Neflamapimod could be a terribly interesting drug for Alzheimer patients.Its mode of action is much more satisfactory than that of monoclonals: it corrects a key metabolic disturbance met with in Alzheimer (hyperactivity of P38 alpha kinase ) which induces synaptic dysfunction. Experimentally its activity has also been demonstrated at the hippocampal level. If I were a big pharma firm, I would immediately try to buy the company behind this drug.

Leave a Comment

Your email address will not be published. Required fields are marked *